REGN
HealthcareRegeneron Pharmaceuticals
Price Chart
Market Data
Financials
XBRL · SEC EDGAR2008–2025(18yr)| Metric | FY 2008 | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025Latest | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $238.5M | $379.3M | $459.1M | $445.8M | $1.4B | $2.1B | $2.8B | $4.1B | $4.9B | $5.9B | $6.7B | $7.9B | $8.5B | $16.1B | $12.2B | $13.1B | $14.2B | $14.3B | +1.0% |
| Gross Profit | $237.5M | $377.6M | $457.0M | $441.6M | $1.3B | $2.0B | $2.7B | $3.9B | $4.7B | $5.7B | $6.5B | $7.5B | — | — | — | — | — | — | — |
| Gross Margin | 99.6% | 99.6% | 99.5% | 99.1% | 93.9% | 94.4% | 95.4% | 94.1% | 96.0% | 96.6% | 96.5% | 94.9% | — | — | — | — | — | — | — |
| Operating Income | -$86.2M | -$74.1M | -$97.5M | -$205.2M | $457.7M | $760.0M | $838.4M | $1.3B | $1.3B | $2.1B | $2.5B | $2.2B | $3.6B | $8.9B | $4.7B | $4.0B | $4.0B | $3.6B | -10.3% |
| Operating Margin | -36.2% | -19.5% | -21.2% | -46.0% | 33.2% | 36.1% | 29.7% | 30.5% | 27.4% | 35.4% | 37.8% | 28.1% | 42.1% | 55.7% | 38.9% | 30.9% | 28.1% | 24.9% | -3.2pp |
| Net Income | -$79.1M | -$67.8M | -$104.5M | -$221.8M | $750.3M | $424.4M | $348.1M | $636.1M | $895.5M | $1.2B | $2.4B | $2.1B | $3.5B | $8.1B | $4.3B | $4.0B | $4.4B | $4.5B | +2.1% |
| Net Margin | -33.2% | -17.9% | -22.8% | -49.7% | 54.4% | 20.2% | 12.3% | 15.5% | 18.4% | 20.4% | 36.4% | 26.9% | 41.3% | 50.2% | 35.6% | 30.1% | 31.1% | 31.4% | +0.3pp |
| Free Cash Flow | -$123.9M | -$169.5M | -$3.3M | -$198.9M | -$124.0M | $427.3M | $410.2M | $652.8M | $961.5M | $1.0B | $1.8B | $2.0B | $2.0B | $6.5B | $4.4B | $3.9B | $3.7B | $4.1B | +11.3% |
| FCF Margin | -52.0% | -44.7% | -0.7% | -44.6% | -9.0% | 20.3% | 14.5% | 15.9% | 19.8% | 17.6% | 27.0% | 25.4% | 23.6% | 40.6% | 36.3% | 29.5% | 25.8% | 28.4% | +2.6pp |
| EPS (Diluted) | — | $-0.86 | $-1.26 | $-2.45 | $6.75 | $3.81 | $3.07 | $5.52 | $7.70 | $10.34 | $21.29 | $18.46 | $30.52 | $71.97 | $38.22 | $34.77 | $38.34 | $41.48 | +8.2% |
1. THE BIG PICTURE
Regeneron is a premier drug-discovery engine currently trapped in a high-stakes race to replace its aging blockbusters before biosimilar competitors and federal price negotiations hollow out its margins. While its proprietary VelociSuite technology continues to produce new candidates, Regeneron Pharmaceuticals’s immediate financial health is tethered to whether the newer EYLEA HD can scale fast enough to offset the 52% quarterly decline in the original EYLEA’s U.S. sales (8-K).
2. WHERE THE RISKS HIT HARDEST
The "integrated" business model is threatened by extreme revenue concentration, as the Sanofi collaboration and the EYLEA franchise combined for 72% of total 2025 revenue (10-K Item 1A). This reliance on a few massive winners becomes a structural vulnerability when facing biosimilar competition, which has already triggered a 42% decline in annual U.S. EYLEA net sales. Furthermore, the strategic priority of "commercial execution" is directly challenged by the Medicare Drug Price Negotiation Program; because EYLEA and EYLEA HD are such significant revenue drivers, they are primary targets for inflation-based rebates and mandatory price resets under the Inflation Reduction Act (10-K Item 1A).
3. WHAT THE NUMBERS SAY TOGETHER
The financial data reveals a company whose top-line growth has stalled at 1.0%—the lowest among its peer group—even as it leads those same peers with a 4.3% buyback yield (XBRL). This suggests management is using its 29.7% FCFFCFFree Cash Flow — cash left after paying for operations and capital investments; what the company can actually spend, save, or return to shareholders margin to support the stock price while the product mix shifts. The divergence between the 3% quarterly revenue growth and the 8% decline in GAAPGAAPGenerally Accepted Accounting Principles — the standard U.S. accounting rules all public companies must follow net income reflects the heavy costs of this transition; EYLEA HD’s 66% growth is not yet large enough in absolute terms to fully replace the lost EYLEA volume (8-K). While Regeneron Pharmaceuticals maintains a strong balance sheet with only $1.0 billion in net debt, its 44.6% gross margin is the lowest in its peer group, reflecting the heavy "profit-sharing" nature of its collaboration-heavy business model (XBRL).
4. IS IT WORTH IT AT THIS PRICE?
At 14.7x forward earnings, Regeneron trades at a modest discount to the peer median of 15.4x. The market is currently pricing in a long-term growth rate of just 0.5% (CAPM analysis). This cautious valuation appears to bake in the 42% drop in EYLEA sales but may ignore the 34% global growth of Dupixent (8-K). If Regeneron can achieve even modest GDP-paced growth of 2.5%, the justified multiple would rise to 23.9x. However, the current discount is justified by the fact that Regeneron’s revenue growth (+1.0%) significantly trails faster-growing peers like Amgen (+10.0%) and Vertex (+8.9%), who do not face the same immediate "patent cliff" pressures (XBRL).
5. WHAT WOULD CHANGE THIS VIEW?
- Cautious if EYLEA HD sales growth decelerates before the next wave of biosimilar launches expected in the second half of 2026 (10-K Item 1A).
- Constructive if the Rensselaer fill/finish facility receives successful validation, easing the manufacturing constraints that currently limit internal capacity (10-K Item 1A).
- Cautious if Sanofi collaboration revenue (41% of total) is impacted by proposed "most-favored-nation" pricing mandates that could force U.S. prices to match lower international levels.
6. BOTTOM LINE
Structural Advantage: A fully integrated R&DR&DResearch & Development — spending on creating new products or technologies suite (VelociSuite) and a proprietary genetics center that allow for rapid, fully human antibody development.
Bottom Line: Regeneron is a high-output scientific powerhouse trading at a "no-growth" valuation, offering a defensive entry point if EYLEA HD can successfully stabilize the ophthalmology franchise.
1. Top 5 Material Risks
- Concentration of Revenue: Regeneron Pharmaceuticals is substantially dependent on EYLEA HD, EYLEA, and Dupixent. In 2025, EYLEA HD and EYLEA combined for 31% of total revenue, while Sanofi collaboration revenue (primarily Dupixent) accounted for 41%.
- Biosimilar Competition: Following the May 2024 expiration of U.S. regulatory exclusivity for EYLEA, biosimilar competition has already impacted sales, with EYLEA U.S. net product sales declining 42% in 2025 compared to 2024. Additional biosimilar launches are expected in the second half of 2026.
- Pricing and Reimbursement Pressures: The Inflation Reduction Act (IRA) subjects products like EYLEA HD and EYLEA to the Medicare Drug Price Negotiation Program and inflation-based rebates. Furthermore, executive orders and proposed Medicare payment models could force Regeneron Pharmaceuticals to match international reference pricing, potentially reducing Medicare spending on its products.
- Manufacturing and Supply Chain Constraints: Regeneron Pharmaceuticals relies on limited internal capacity at its Rensselaer, New York and Limerick, Ireland facilities. Failure to maintain cGMP compliance or successfully expand capacity—such as the ongoing validation of the Rensselaer fill/finish facility—could delay product launches or result in inventory write-downs.
- Third-Party Dependency: Regeneron Pharmaceuticals relies on two distributor customers for 77% of its total gross product revenue as of 2025. The loss of these customers or a shift in their purchasing behavior would directly impact net trade accounts receivable and overall revenue.
2. Company-Specific Risks
- Collaboration Litigation: Regeneron Pharmaceuticals is currently in litigation with Sanofi regarding the Antibody Collaboration, which creates uncertainty regarding the future of the partnership and access to material information necessary for commercialization.
- Combination Product Complexity: Many products, such as the EYLEA HD pre-filled syringe, are regulated as combination products. The FDA issued a Complete Response Letter (CRL) in October 2025 for the EYLEA HD pre-filled syringe, illustrating the risk that device-related regulatory hurdles can delay commercialization.
- Clinical Trial Setbacks: Regeneron Pharmaceuticals has experienced recent failures, such as the May 2025 announcement that a Phase 3 trial for itepekimab in COPD did not meet its primary endpoint, and CRLs for odronextamab in 2024 and 2025, which delay the expansion of the product pipeline.
- Geopolitical Exposure: Regeneron Pharmaceuticals faces risks from trade restrictions and the BIOSECURE Act, which may limit the ability to engage China-based suppliers for raw materials and services essential to clinical and commercial operations.
3. Regulatory/Legal Risks
- Healthcare Fraud and Abuse: Regeneron Pharmaceuticals is subject to ongoing civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts regarding business practices.
- Medicaid and 340B Compliance: Regeneron Pharmaceuticals faces potential civil monetary penalties and exclusion from government programs if it fails to accurately report pricing data or comply with 340B ceiling price requirements, which are subject to complex and evolving interpretations.
- Pharmacovigilance: Failure to maintain a Qualified Person Responsible for Pharmacovigilance (QPPV) or comply with safety reporting requirements in the EEA could lead to the suspension of marketing authorizations.
4. Financial Impact Map
Biosimilar Competition → Net Product Sales → 42% decline in EYLEA U.S. net product sales in 2025 vs 2024. Medicare Drug Price Negotiation Program → Net Product Sales → Potential reduction in reimbursement levels for products covered under Medicare Parts B and D. Manufacturing Facility Failures → Inventory / Operating Expenses → Risk of inventory write-downs or impairment charges, similar to the 2022/2021 REGEN-COV inventory write-downs. Distributor Customer Concentration → Net Trade Accounts Receivable → 77% of gross product revenue is concentrated in two customers, creating credit and collection risk. Collaboration Litigation → Collaboration Revenue → Potential disruption to the 41% of total revenue derived from the Sanofi Antibody Collaboration.
Recent Filings
| Form | Filed | Period |
|---|---|---|
| 10-K | Feb 2026 | Dec 2025 |
| 8-K | Jan 2026 | — |
| 10-Q | Oct 2025 | Sep 2025 |
| 14A | Apr 2025 | — |
AI-extracted key facts from press releases and SEC filings. Significance 1–10.
Regeneron partners with TriNetX to access 300 million patient records for drug discovery
- ▸Regeneron gains access to TriNetX network of 300 million de-identified patient records
- ▸Collaboration targets drug discovery, development, and digital health solution initiatives
- ▸Integration of large-scale genomic and proteomic data with phenotypic health records
- ▸Strategic focus on accelerating research for consumers, patients, and providers
Regeneron Q3 Revenue $3.75B Beats Estimates, EPS $11.83 Tops $9.59 Forecast
- ▸Q3 revenue $3.75B, exceeding analyst estimates of $3.59B
- ▸Q3 EPS $11.83, significantly beating consensus estimate of $9.59
- ▸Stock closed 11.8% higher on October 28th following earnings release
- ▸Bank of America previously upgraded stock to Buy with $860 price target
- ▸Company developing weight loss drugs focused on retaining lean muscle mass
Regeneron Dupixent Receives Multiple Global Regulatory Approvals for Pediatric and Adult Indications
- ▸FDA approved Dupixent for allergic fungal rhinosinusitis in patients 6 years and older
- ▸EMA CHMP recommended Dupixent for chronic spontaneous urticaria in children 2 to 11
- ▸Japan MHLW authorized Dupixent for severe bronchial asthma in children 6 to 11
- ▸Analysts raised price targets citing Dupixent growth and pipeline potential
- ▸Fair value estimate increased to $873.78 per share
Regeneron reports positive Phase 3 obesity trial results for olatorepatide, plans global program
- ▸Olatorepatide Phase 3 trial shows significant weight loss outcomes
- ▸Company plans to initiate global Phase 3 clinical program
- ▸Stock trading at $790.76 as of March 2, 2026
- ▸Fair value estimated at $893.88, suggesting potential undervaluation
- ▸Q4 2025 earnings beat reported in late January